| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Moore Paul Andrew, Chief Scientific Officer
Received 25,000 shares by exercise or conversion ($146K) · Sold 39,741 shares ($1.04M) |
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 13 Nov 2026 | 144 |
| 09 Nov 2026 |
8-K/A: Financial Statements and Exhibits
As previously announced, on June 28, 2026, Zymeworks Inc. (“Zymeworks” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Theravance Biopharma, Inc. (“Theravance”) and Zymeworks Merger Sub 1, a w... |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (November 9, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, to... |
| 26 Oct 2026 | ARS |
| 26 Oct 2026 | DEFA14A |
| 26 Oct 2026 |
Proxy statement: annual meeting on December 15, 2026
CEO pay $6.6M, up 20% · say-on-pay vote |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 |
| 16 Oct 2026 | PRE 14A |
| 09 Oct 2026 |
Form 4: Schayowitz Adam, EVP, Head of R&D
Received 37,037 shares by exercise or conversion · Sold 13,832 shares ($358K) |
| 09 Oct 2026 | 144 |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSE... |
| 25 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Vancouver, British Columbia (August 6, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, toda... |
| 06 Jul 2026 |
Form 4: Hollywood Mark, EVP & Chief Operating Officer
Received 939 shares as a grant or award ($20.9K) |
| 29 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This AGREEMENT AND PLAN OF MERGER, dated as of June 28, 2026 (this “Agreement”), is entered into by and among Theravance Biopharma, Inc., an exempted company with limited liability incorporated under the Laws of the Cayman Islands (the “... |
| 15 May 2026 |
Form 4: Schneider Paul R, EVP, General Counsel
Granted 178,000 Stock Option (Right to Buy) · Granted 119,000 Restricted Stock Unit |
Loading...